Leading drug company Ranbaxy Laboratories on Wednesday said it had invested almost $300 million across manufacturing facilities to ensure safety and efficacy of its products in the global markets.
In a statement issued in New Delhi, Ranbaxy CEO and managing director, Arund Sawhney said in the recent years the company has made significant improvements in the way its conduct business to ensure greater quality control. “We have made investments of over $300 million in our manufacturing facilities to install state-of-the-art technologies apart from several other measures”, he said.
Stating that all these measures have taken to make the company look different, Mr. Sawhney said, “The steps we have taken over the recent years reflect the wide-ranging efforts of the current board and management to address certain conduct of the past and ensure that Ranbaxy moves forward with integrity and professionalism in everything we do.”
Mr. Sawhney said Ranbaxy has instituted a rigorous new code of conduct for all employees, with clear accountability for compliance. “Several actions have been taken including upgrading its business and manufacturing processes and building a culture of accountability and excellence across all
levels of the organisation. The new team is committed to building and maintaining a culture of accountability, steadfast regulatory adherence and continuous improvement in quality across all levels of the organisation,” the statement said.
Last week, pleading guilty to felony charges relating to manufacture and distribution of certain adulterated drugs made at two India units, the US subsidiary of Ranbaxy had agreed to pay $500 million in settlement with the US authorities. The generic drugs at issue were manufactured at Ranbaxy's facilities in Paonta Sahib and Dewas in India.